Add a GLP-1 Receptor Agonist to Improve Glycemic Control
The most important recommendation is to add a long-acting GLP-1 receptor agonist (specifically dulaglutide, liraglutide, or semaglutide) to this patient's regimen, as this will lower A1C without worsening kidney function and provides cardiovascular and renal protection. 1
Immediate Medication Adjustments Required
1. Reduce Metformin Dose NOW
With an eGFR of 45 mL/min/1.73 m², this patient's metformin dose must be halved immediately 1. The current regimen likely exceeds safe dosing for this level of kidney function. At eGFR 30-44, metformin should be reduced to a maximum of 1000 mg/day, and at eGFR 45-59, dose reduction should be strongly considered 2, 1.
2. Continue Jardiance (Empagliflozin)
Keep empagliflozin at 10 mg daily despite the eGFR of 45 2, 1. While the FDA label states "use not recommended with eGFR <45," the 2022 KDIGO/ADA consensus explicitly recommends continuing SGLT2 inhibitors once initiated even at lower eGFR levels for their kidney and cardiovascular benefits 2. The glucose-lowering effect diminishes at this eGFR, but the cardiorenal protection persists 3, 4.
3. Discontinue or Reduce Glipizide
Strongly consider stopping glipizide 2, 1. Sulfonylureas carry significant hypoglycemia risk in CKD and should be initiated "conservatively" and titrated slowly. Given that you're adding a GLP-1 RA (which is far superior), glipizide becomes redundant and dangerous. If you must continue it temporarily, reduce to the minimum dose (2.5 mg once daily) 2.
Primary Addition: GLP-1 Receptor Agonist
Add one of these GLP-1 RAs with proven cardiovascular benefit 1:
- Dulaglutide 0.75 mg weekly (no dose adjustment needed; safe to eGFR >15) 1
- Liraglutide 1.2-1.8 mg daily (no dose adjustment needed) 1
- Semaglutide 0.5-1 mg weekly (no dose adjustment needed) 1
Why GLP-1 RAs are the answer here:
- They reduce A1C by 1-1.5% without worsening kidney function 1
- They slow eGFR decline and reduce albuminuria 2
- They reduce cardiovascular events (MACE) 2
- Low hypoglycemia risk when used alone or with metformin/SGLT2i 1
- They cause weight loss (beneficial for this patient's metabolic profile) 5
Start low and titrate slowly to minimize GI side effects (nausea, vomiting) 1. For example, with dulaglutide, begin at 0.75 mg weekly for 4 weeks, then increase to 1.5 mg if tolerated and A1C target not met.
Critical Caveat About Drug Interactions
Do NOT combine GLP-1 RAs with DPP-4 inhibitors 1. If this patient were on a DPP-4 inhibitor (sitagliptin, linagliptin, etc.), it would need to be stopped before starting the GLP-1 RA.
When adding a GLP-1 RA to glipizide (if you keep it), the hypoglycemia risk increases significantly 1. This is another strong reason to discontinue the sulfonylurea.
Why NOT Other Options
Insulin
While insulin can be used in CKD, it requires conservative titration to avoid hypoglycemia 2 and doesn't provide the cardiorenal benefits of GLP-1 RAs. Reserve this for later if needed.
DPP-4 Inhibitors
These require dose adjustment at eGFR 45 (e.g., sitagliptin max 50 mg daily) 2 and are inferior to GLP-1 RAs for cardiovascular outcomes and A1C reduction 1. The 2022 KDIGO guideline explicitly prioritizes GLP-1 RAs over DPP-4 inhibitors 1.
Thiazolidinediones (Pioglitazone)
No dose adjustment needed in CKD 2, but causes fluid retention and weight gain—undesirable in this patient with hypertriglyceridemia and likely volume-sensitive kidney disease.
Expected Outcomes
With this regimen adjustment:
- A1C should decrease by 0.8-1.2% (from 7.8% to ~6.6-7.0%) 6, 5
- eGFR will likely stabilize or improve slightly over 6 months 3, 7
- Weight loss of 2-3 kg expected 5
- Systolic BP reduction of 3-5 mmHg 5
- Reduced cardiovascular and kidney disease progression risk 2, 4
Monitoring Plan
- Check eGFR in 1 month after metformin dose reduction
- Recheck A1C in 3 months after GLP-1 RA initiation
- Monitor for hypoglycemia if glipizide continued (check fingersticks if symptomatic)
- Assess for GI side effects at 2-4 weeks (nausea, vomiting, diarrhea)
- Continue monitoring vitamin B12 annually on metformin 1
Common Pitfall to Avoid
Do not stop empagliflozin just because eGFR is 45. The 2022 KDIGO/ADA consensus supersedes older FDA labeling restrictions. The initial eGFR "dip" of 3-5 mL/min with SGLT2 inhibitors is hemodynamic (reduced intraglomerular pressure), not nephrotoxic, and reverses after discontinuation 3, 7. This dip actually predicts long-term kidney protection.